The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
124
ALN-AGT01 will be administered by subcutaneous (SC) injection.
Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
Irbesartan will be administered orally.
Clinical Trial Site
Edinburgh, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
Manchester, United Kingdom
Number of Participants with Adverse Events (AEs)
Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months
Change from Baseline in Blood Angiotensinogen (AGT) Level
Time frame: Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months
Maximum Observed Plasma Concentration (Cmax) of ALN-AGT01 and of Potential Metabolites
Time frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99
Area Under the Concentration-time Curve (AUC) of ALN-AGT01 and of Potential Metabolites
Time frame: Parts A, B and E: Up to Day 15; Part D: Up to Day 99
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Irbesartan-matching placebo will be administered orally.